Disease Landscape and Forecast Insights

MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…

Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small…

Recent launches of trastuzumab biosimilars (Celltrion/Mundipharma’s Herzuma, Samsung Bioepis/Merck & Co.’s Ontruzant, Amgen/Allergan’s Kanjinti) have expanded the biosimilar sector of the…

Celltrion’s Herzuma (trastuzumab) is the first biosimilar of Roche’s blockbuster HER2-targeted therapy, Herceptin, to launch in Europe. This series tracks uptake of Herzuma and medical…

Biomarker-driven prescribing is entrenched in indications such as non-small-cell lung cancer (NSCLC) and malignant melanoma and is playing an increasingly important role in indications such as…

MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…

Immune checkpoint inhibitors continue to revolutionize the treatment of a wide range of solid-tumor and hematological malignancies, with a growing list of approvals and label expansions. The Immune…

Market Outlook  Therapeutic options for gastroesophageal cancer are limited, with only two targeted agents approved for the treatment of gastric and GEJ adenocarcinoma (neither agent is approved…

Market Outlook  Squamous cell carcinoma of the head and neck ( SCCHN ) is an anatomically and biologically heterogeneous disease, which has historically proven a complex challenge for drug…

Biomarker-targeted therapies are distinguished from other oncology drugs in that they are accompanied by a diagnostic test that can identify a specific patient type most likely to benefit from…

Recent launches of Celltrion’s Truxima (rituximab) and Sandoz’s Rixathon (rituximab) have expanded the biosimilar sector of the European oncology market. In the United States, only a single…

The treatment of both solid and hematological cancers is associated with a wide range of serious side effects, including chemotherapy-associated neutropenia and anemia, nausea and vomiting, and…